• Users Online: 147
  • Print this page
  • Email this page
Year : 2021  |  Volume : 1  |  Issue : 4  |  Page : 643-647

Role of topical high concentration levofloxacin 1.5% in bacterial keratitis

Dr. Shroff's Charity Eye Hospital, New Delhi, India

Correspondence Address:
Dr. Gunjan Budhiraja
Dr. Shroff's Charity Eye Hospital, 5027, Kedarnath Ln, Daryaganj, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijo.IJO_3745_20

Rights and Permissions

Bacterial keratitis is a common clinical condition that may lead to visual impairment if untreated. We report our clinical experience of treating bacterial keratitis with levofloxacin (LVFX) 1.5% ophthalmic solution in 10 patients. Eight patients with confirmed bacterial keratitis received monotherapy with LVFX 1.5% and two patients received an additional antibiotic. All patients demonstrated progressive improvement in keratitis and visual acuity over 1 to 2 weeks of treatment. There were no treatment-emergent adverse events. LVFX 1.5% solution is an effective and well-tolerated option for the treatment of bacterial keratitis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal